Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic drug giant Teva Pharmaceutical Industries (NYSE:TEVA) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Teva and see what CAPS investors are saying about the stock right now.

Teva facts

Headquarters (founded)

Petach Tikva, Israel (1901)

Market Cap

$32.6 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$20.3 billion

Management

CEO Dr. Jeremy Levin (since 2010)
CFO Eyal Desheh (since 2008)

Return on Equity (average, past 3 years)

12.4%

Cash/Debt

$2.9 billion / $14.7 billion

Dividend Yield

2.8%

Competitors

Actavis
Novartis
Mylan

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 1,769 members who have rated Teva believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, MMcCabeNMC, succinctly summed up the Teva bull case for our community:

Teva is a huge generic drug maker, with some outreach into the primary drug market. The company's balance sheet is strong, and the stock pays a reasonable dividend. With governments emphasizing cost controls for medical expense, Teva has a guaranteed market.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.